Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS)
V Koneti Rao, Jorge A Carrasquillo, Janet K Dale, Stephen L Bacharach, Millie Whatley, Faith Dugan, Jean Tretler, Thomas Fleisher, Jennifer M Puck, Wyndham Wilson, Elaine S Jaffe, Nilo Avila, Clara C Chen, Stephen E Straus, V Koneti Rao, Jorge A Carrasquillo, Janet K Dale, Stephen L Bacharach, Millie Whatley, Faith Dugan, Jean Tretler, Thomas Fleisher, Jennifer M Puck, Wyndham Wilson, Elaine S Jaffe, Nilo Avila, Clara C Chen, Stephen E Straus
Abstract
Autoimmune lymphoproliferative syndrome (ALPS) is associated with mutations that impair the activity of lymphocyte apoptosis proteins, leading to chronic lymphadenopathy, hepatosplenomegaly, autoimmunity, and an increased risk of lymphoma. We investigated the utility of fluorodeoxyglucose positron emission tomography (FDG-PET) in discriminating benign from malignant lymphadenopathy in ALPS. We report that FDG avidity of benign lymph nodes in ALPS can be high and, hence, by itself does not imply presence of lymphoma; but FDG-PET can help guide the decision for selecting which of many enlarged nodes in ALPS patients to biopsy when lymphoma is suspected.
2006 Wiley-Liss, Inc.
Source: PubMed